1-[4-(甲基磺酰基)苯基]哌嗪 | 187669-60-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-[4-(甲基磺酰基)苯基]哌嗪
• 中文别名: 1-(4-甲基磺酰苯基)哌嗪；1-(4-甲磺酰基苯基)哌嗪
• 英文名称: 1-(4-methanesulfonyl-phenyl)-piperazine
• 英文别名: 1-(4-(methylsulfonyl)phenyl)piperazine；1-[4-(Methylsulfonyl)phenyl]piperazine；1-(4-methylsulfonylphenyl)piperazine
• CAS: 187669-60-9
• 化学式: C₁₁H₁₆N₂O₂S
• mdl: MFCD03648601
• 分子量: 240.326
• InChiKey: KNQFDOLIXOOIGX-UHFFFAOYSA-N

物化性质

• 熔点：
  136～138℃
• 沸点：
  136～138℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-[4-(甲基磺酰基)苯基]哌嗪 、 2-吗啉-5-硝基苯甲酸 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 [4-(4-methanesulfonyl-phenyl)-piperazin-1-yl]-(2-morpholin-4-yl-5-nitro-phenyl)-methanone
  参考文献：
  名称：

  Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors

  摘要：

  Screening of the Roche compound library led to the identification of the benzoylpiperazine 7 as a structurally novel GlyT1 inhibitor. The SAR which was developed in this series resulted in the discovery of highly potent compounds displaying excellent selectivity against the GlyT2 isoform, drug-like properties, and in vivo efficacy after oral administration. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.086
• 作为产物：
  描述：

  1-苄基-4-[4-(甲基磺酰基)苯基]哌嗪 在 palladium hydroxide, 20 wt% on carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 1-[4-(甲基磺酰基)苯基]哌嗪
  参考文献：
  名称：

  [EN] IMIDAZOLE DERIVATIVES
  [FR] DÉRIVÉS D'IMIDAZOLE

  摘要：

  本文描述的是式(I)、式la或式lb的化合物。式(I)、式la或式lb的化合物作为DGATl抑制剂，在预防、治疗或作为治疗高脂血症、糖尿病和肥胖症的药物中可能有用。

  公开号：

  WO2012064569A1

文献信息

• [EN] 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS<br/>[FR] DERIVES DE PIPERAZINES 1-ARYL-4-SUSBTITUES UTILISES EN TANT QU'ANTAGONISTES DU CCR1 DANS LE TRAITEMENT DE L'INFLAMMATION ET DES TROUBLES IMMUNITAIRES
  申请人：CHEMOCENTRYX INC

  公开号：WO2003105853A1

  公开（公告）日：2003-12-24

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了作为CCR1受体强效拮抗剂的化合物，并且已经在动物炎症测试中进一步确认，炎症是CCR1的典型疾病状态之一。这些化合物通常是芳基哌嗪衍生物，在制药组合物、治疗CCR1介导疾病的方法以及用于鉴定竞争性CCR1拮抗剂的检测中具有用途。
• Substituted piperazines
  申请人：ChemoCentryx, Inc.

  公开号：US20040162282A1

  公开（公告）日：2004-08-19

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了作为CCR1受体强效拮抗剂的化合物，并且这些化合物在动物炎症测试中进一步得到确认，炎症是CCR1的典型疾病状态之一。这些化合物通常是芳基哌嗪衍生物，在制药组合物、治疗CCR1介导疾病的方法以及用作竞争性CCR1拮抗剂鉴定的检测中是有用的。
• Nickel‐Catalyzed Amination of (Hetero)aryl Halides Facilitated by a Catalytic Pyridinium Additive
  作者：Dongyang Han、Sasa Li、Siqi Xia、Mincong Su、Jian Jin

  DOI：10.1002/chem.202002800

  日期：2020.9.25

  An efficient and operationally simple Ni‐catalyzed amination protocol has been developed. This methodology features a simple NiII salt, an organic base and catalytic amounts of both a pyridinium additive and Zn metal. A diverse number of (hetero)aryl halides were coupled successfully with primary and secondary alkyl amines, and anilines in good to excellent yields. Similarly, benzophenone imine gave

  已经开发了有效且操作简单的镍催化胺化方案。该方法具有简单的Ni II盐，有机碱以及催化量的吡啶鎓添加剂和Zn金属的特征。多种（杂）芳基卤化物与伯，仲烷基胺和苯胺成功偶联，收率良好。同样，二苯甲酮亚胺以优异的收率得到了相应的N芳基化产物。
• [EN] ADENOSINE RECEPTOR BINDING COMPOUNDS<br/>[FR] COMPOSÉS SE LIANT AU RÉCEPTEUR DE L'ADÉNOSINE
  申请人：NIKANG THERAPEUTICS INC

  公开号：WO2020014332A1

  公开（公告）日：2020-01-16

  The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.

  本发明涉及化学式（I）的药物化合物和组合物，以及使用这些化合物和组合物进行治疗的方法，特别是用于治疗和/或预防增殖性疾病，如癌症。如本文进一步描述的化合物（I）被显示为腺苷A2A受体的调节剂，并表现出抗增殖活性。因此，这些化合物对于治疗增殖性疾病如癌症以及其他与腺苷受体相关的疾病条件包括炎症性疾病、肾脏疾病、糖尿病、血管疾病、肺部疾病或自身免疫疾病是有用的。
• Sulfanyl substituted phenyl methanones
  申请人：Jolidon Synese

  公开号：US20060149062A1

  公开（公告）日：2006-07-06

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 3 , X, X 1 , and n are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors of the glycine transporter 1 (GlyT-1) for the treatment CNS disorders, such as schizophrenia, cognitive impairment, and Alzheimer's disease.

  本发明涉及以下式I的化合物，其中R1、R2、R3、X、X1和n如规范中所定义，并且其药用可接受的酸盐。这些化合物是良好的甘氨酸转运蛋白1（GlyT-1）抑制剂，用于治疗中枢神经系统疾病，如精神分裂症、认知障碍和阿尔茨海默病。